Literature DB >> 20927006

Managing spasticity with drugs.

O Simon1, A P Yelnik.   

Abstract

Spasticity is a common symptom observed after pyramidal system lesion. The treatment of spasticity has considerably changed during last years, notably with the generalization of Botulinum toxin use. However, the treatment of spasticity should consider all therapeutic possibility in accordance with patient status and objective. Drugs are only a part of the treatment and physical therapy must always be used. Others treatments such as surgery, orthosis, occupational therapy must also be discussed individually. Several guidelines are now available for Botulinum toxin treatment but only the French guidelines consider all drug therapies. This review addresses the different drugs commonly used on the basis of an extensive review of literature. Some facts are clearly established by randomized controlled trials but a certain number of questions remains unclear and only clinical experience and consensus can guide injectors.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20927006

Source DB:  PubMed          Journal:  Eur J Phys Rehabil Med        ISSN: 1973-9087            Impact factor:   2.874


  19 in total

Review 1.  Latest approaches for the treatment of spasticity and autonomic dysreflexia in chronic spinal cord injury.

Authors:  Alexander G Rabchevsky; Patrick H Kitzman
Journal:  Neurotherapeutics       Date:  2011-04       Impact factor: 7.620

2.  Optical inhibition of motor nerve and muscle activity in vivo.

Authors:  Holly Liske; Chris Towne; Polina Anikeeva; Shengli Zhao; Guoping Feng; Karl Deisseroth; Scott Delp
Journal:  Muscle Nerve       Date:  2013-04-30       Impact factor: 3.217

3.  A Review of Spasticity Treatments: Pharmacological and Interventional Approaches.

Authors:  Eric Chang; Nilasha Ghosh; Daniel Yanni; Sujin Lee; Daniela Alexandru; Tahseen Mozaffar
Journal:  Crit Rev Phys Rehabil Med       Date:  2013

4.  Requirement of neuronal connexin36 in pathways mediating presynaptic inhibition of primary afferents in functionally mature mouse spinal cord.

Authors:  Wendy Bautista; James I Nagy; Yue Dai; David A McCrea
Journal:  J Physiol       Date:  2012-05-21       Impact factor: 5.182

5.  The short-term effect of ultrasound and peripheral nerve stimulator-guided femoral nerve block with phenol on the outcomes of patients with traumatic spinal cord injury.

Authors:  Yasin Demir; Ayça Uran Şan; Serdar Kesikburun; Evren Yaşar; Bilge Yılmaz
Journal:  Spinal Cord       Date:  2018-05-22       Impact factor: 2.772

Review 6.  Rehabilitation Strategies after Spinal Cord Injury: Inquiry into the Mechanisms of Success and Failure.

Authors:  Marie-Pascale Côté; Marion Murray; Michel A Lemay
Journal:  J Neurotrauma       Date:  2016-11-21       Impact factor: 5.269

7.  Use of botulinum toxin type A in the management of patients with neurological disorders: a national survey.

Authors:  Nicola Smania; Carlo Colosimo; Anna Rita Bentivoglio; Giorgio Sandrini; Alessandro Picelli
Journal:  Funct Neurol       Date:  2013 Oct-Dec

8.  Management of spasticity with onabotulinumtoxinA: practical guidance based on the italian real-life post-stroke spasticity survey.

Authors:  Giorgio Sandrini; A Baricich; C Cisari; Stefano Paolucci; Nicola Smania; A Picelli
Journal:  Funct Neurol       Date:  2018 Jan/Mar

9.  Treatment of spasticity in spinal cord injury with botulinum toxin.

Authors:  Ramiro Palazón-García; Mónica Alcobendas-Maestro; Ana Esclarin-de Ruz; Ana María Benavente-Valdepeñas
Journal:  J Spinal Cord Med       Date:  2018-06-05       Impact factor: 1.985

10.  Enhancing KCC2 activity decreases hyperreflexia and spasticity after chronic spinal cord injury.

Authors:  Jadwiga N Bilchak; Kyle Yeakle; Guillaume Caron; Dillon Malloy; Marie-Pascale Côté
Journal:  Exp Neurol       Date:  2021-01-13       Impact factor: 5.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.